Some researchers suggested the P2Y12 inhibitormonotherapy can’t reverse the diabetes-induced high risk of ischemic events bycomparing it with different antiplatelet therapies in Korean patients with orwithout diabetes, which suggested that ACS patients, who are at high risk ofischemia need to maintain potent antiplatelet agents [42]. Here, P2RY12 is linked to diabetes mellitus.